Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer (IMPACT-CRC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02117466|
Recruitment Status : Recruiting
First Posted : April 21, 2014
Last Update Posted : October 8, 2018
In this study the investigators will evaluate the uptake of 89Zirconium labeled cetuximab in extra-hepatic colorectal metastases. The investigators hypothesize that uptake of 89Zr-cetuximab is required for response to cetuximab. If no uptake is present the investigators will escalate the dose cetuximab and repeat the 89Zr-cetuximab PET.
The investigators will evaluate the clinical benefit rate of cetuximab in the patients with and without uptake. The ultimate goal is to create a selection tool that can predict response of cetuximab.
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Colorectal Cancer||Drug: Dose escalation cetuximab Drug: Standard dose cetuximab||Phase 1 Phase 2|
Rationale: Currently, third line systemic treatment for patients with advanced, wild type K-RAS and as has recently been demonstrated with wild type N-RAS (thereafter referred to as wild type RAS) colorectal cancer (CRC) includes epidermal growth factor receptor (EGFR) inhibition with the anti-EGFR antibody cetuximab. This type of treatment has a modest but significant beneficial activity in this patient group with improved progression-free and overall survival. Although it is known that patients with advanced wild type RAS CRC will not respond to anti-EGFR treatment, it is not understood why patients with wild type RAS CRC do not all benefit from this type of therapy. Apart from other potential gene mutations involved in response to treatment, differences in the variability of pharmacokinetics may play a crucial role in the response to anti-EGFR treatment. In non-responders insufficient drug accumulation may occur in the tumor due to pharmacokinetic processes, such as cetuximab sequestration in the liver which expresses high levels of EGFR, or due to low levels of EGFR expression in tumor lesions. Our main hypothesis is that uptake of cetuximab in metastases is required for response and that achieving cetuximab uptake by increasing its dose will result in improved clinical benefit in patients with advanced CRC with wild type RAS.
- to demonstrate 89Zr-cetuximab uptake in non-hepatic metastases at standard dose or at cohort wise increased cetuximab doses (dose escalation).
- to determine the association between 89Zr-cetuximab uptake in non-hepatic metastases and treatment response.
PART II To determine the response rate with an optimized dose of cetuximab as has been selected in part 1 in patients without 89Zr-cetuximab tumor uptake at standard dose of cetuximab (dose extension).
Study design: This is a multicentre non-randomized intervention study; phase I-II dose escalation/extension study.
Study population: Patients with histopathologically confirmed advanced CRC with wild type RAS, without local treatment options, aged ≥ 18 years, with a life expectancy of at least 12 weeks, who are candidates for anti-EGFR antibody monotherapy (3rd line palliative treatment).
Intervention: In the first part we will perform an exploratory PET study in patients with metastasized, RAS wild type CRC without local treatment options, who will be treated with cetuximab. We hypothesize that uptake of 89Zr-cetuximab in metastases is required for response to cetuximab. We will analyze targeting of 89Zr-cetuximab to metastases and the association between 89Zr-cetuximab tumor uptake and tumor response. Early response evaluation will be done with 18F-FDG PET. In a subgroup of 20 patients with metastasis within the field of view (18 cm) including the heart, tumor perfusion will be measured with 15O-water PET scans. In addition, we will investigate the hypothesis that increasing the cetuximab dose results in uptake in patients without uptake in metastases of 89Zr-cetuximab when cetuximab is given at the standard dose regimen. In the second part we will study whether dose adjustments based on 89Zr-cetuximab targeting results in an improved response and clinical benefit rate. In addition, EGFR expression and saturation with cetuximab is studied in tumor biopsies obtained during treatment. Molecular pathways activated by EGFR and kinase activities as well as phosphoproteomics will be studied in tumor biopsies and skin biopsies before and after start of treatment. In addition, the relation of microRNA (miRNA) and peptide profiles in relation to response to therapy will be studied.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||85 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer|
|Study Start Date :||April 2014|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||March 2019|
Standard dose cetuximab
Uptake of 89Zr-cetuximab: continue standard dose (500mg/m2 bsa) (standard care)
Drug: Standard dose cetuximab
500mg/m2 bsa cetuximab (described in the first arm)
Experimental: Dose escalation cetuximab
No 89Zr-cetuximab uptake: dose escalation in a 3x3 cohort design (with maximal 50% dose increase each cohort; with a maximum of 2000 mg/m2 bsa every two weeks)
Drug: Dose escalation cetuximab
dose escalation of cetuximab (described in the second arm)
- Uptake (SUV) of 89Zr-cetuximab in extra-hepatic metastases on PET-scan [ Time Frame: 6 days post injection ]
- Clinical Benefit Rate [ Time Frame: From date of first cetuximab injection until the date of first documented progression (median time to progression 2.5 months) ]Complete response, partial response and stable disease (according to RECIST 1.1) on CT-scan (every 2 months)
- Early response evaluation with 18F-FDG PET [ Time Frame: two weeks after start treatment ]Compare baseline 18F-FDG PET and the on treatment 18F-FDG PET (after 2 weeks of treatment).
- Tumor perfusion as early response evaluation (measured with 15O-H2O-PET) [ Time Frame: two weeks after start treatment ]
Compare baseline 15O-H2O-PET and the on treatment 15O-H2O-PET (after 2 weeks of treatment).
The 15O-H2O-PET will be done in a subgroup of 20 patients, which have metastases within 18 cm field of view including the heart/ aorta.
- Overall survival [ Time Frame: From date first cetuximab injection until the date of death (median overall survival 10 months) ]
- Progression Free Survival [ Time Frame: From date of first cetuximab injection until the date of first documented progression (median time to progression 2.5 months) ]
First year: CT-scan every 2 months (RECIST 1.1)
After 1 year: CT-scan every 3 months (RECIST 1.1)
- Skin toxicity and hypomagnesemia as early response marker [ Time Frame: From date of first cetuximab injection until the date of first documented progression (median time to progression 2.5 months) ]Every two weeks, graded according to CTCAE v 4.0
- Quality of life (QoL) and health related QoL [ Time Frame: From date of first cetuximab injection until the date of first documented progression (median time to progression 2.5 months) ]
- EQ-5D-3L (quality of Life questionnaire); every 2 months
- FACT-EGFRI-18 (quality of Life questionnaire, specially for skin toxicity caused by anti-EGFR therapy); every 2 weeks untill week 8, hereafter every two months
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02117466
|Radboud University Medical Centre Nijmegen||Not yet recruiting|
|Nijmegen, Gelderland, Netherlands, 6500 HB|
|Contact: Eline Boon Eline.email@example.com|
|Sub-Investigator: W van der Graaf, MD, PhD|
|Sub-Investigator: W Oyen, MD PhD|
|VU medical centre||Recruiting|
|Amsterdam, Netherlands, 1007 MB|
|Contact: EJ van Helden, MD 0031 20 44 40595 firstname.lastname@example.org|
|Principal Investigator: CW Menke, MD, PhD|
|Principal Investigator: HWM Verheul, MD, PhD|
|University Medical Centre Groningen||Not yet recruiting|
|Groningen, Netherlands, 9700 RB|
|Contact: Greetje de Vries email@example.com|
|Sub-Investigator: E.G.E. de Vries, PhD. Dr.|
|Sub-Investigator: G.A.P. Hospers, PhD. Dr.|